Drugs / Orantinib
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00024206 | Jul 2001 → Jul 2003 | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00024063 | — | breast cancer, colorectal cancer, gastric cancer, kidney cancer +4 | Jonsson Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00784290 | Sep 2003 → Oct 2010 | hepatocellular carcinoma | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01465464 | Dec 2010 → Jun 2014 | hepatocellular carcinoma | Taiho Pharmaceutical Co., Ltd. | Terminated | Missed primary |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Orantinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00784290 ↗ |
| Known as | NSC-702827 | ChEMBL registry synonym — accepted as the source's own label CHEMBL274654 ↗ |
| Known as | SU-006668 | ChEMBL registry synonym — accepted as the source's own label CHEMBL274654 ↗ |
| Known as | SU-6668 | ChEMBL registry synonym — accepted as the source's own label CHEMBL274654 ↗ |
| Known as | TSU-68 | “Orantinib (TSU-68)” NCT01465464 ↗1“Orantinib (TSU-68)” NCT00784290 ↗ |
| Action | Inhibit | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL274654 ↗1“multiple receptor tyrosine kinase inhibitor” NCT00784290 ↗ |
| Modality | Small molecule | “Orantinib is an orally administered, small-molecule, multiple receptor tyrosine kinase inhibitor” NCT00784290 ↗ |
| Route | Oral | “Given orally” NCT00024206 ↗ |
| Target | KDR | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL274654 ↗ |